Dyne Therapeutics (DYN) Stock Statistics & Valuation Metrics

Dyne Therapeutics has a market cap or net worth of $1.31B. The enterprise value is $723.07M.

Dyne Therapeutics has 141,545,360 shares outstanding. The number of shares has decreased by -2.65% in one year.

Dyne Therapeutics’s return on equity (ROE) is -0.50 and return on invested capital (ROIC) is -52.60%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Dyne Therapeutics had revenue of 0.00 and earned -317.42M in profits. Earnings per share was -3.37.

In the last 12 months, operating cash flow was -319.73M and capital expenditures -3.17M, giving a free cash flow of -322.89M billion.

Dyne Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dyne Therapeutics upcoming earnings date is Jul 31, 2025, Before Open (Confirmed).

Dyne Therapeutics as a current ratio of 15.60, with Debt / Equity ratio of 3.49%

In the past 12 months, Dyne Therapeutics has paid 0.00 in taxes.

Dyne Therapeutics EV to EBITDA ratio is -5.73, with an EV/FCF ratio of -6.13.

Dyne Therapeutics has $677.49M in cash and marketable securities with $23.33M in debt, giving a net cash position of -$654.16M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Dyne Therapeutics is $37.54, which is 11.43% higher than the current price. The consensus rating is Strong Buy